Atacand Receives FDA Approval For Hypertension
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Atacand Receives FDA Approval For Hypertension

WAYNE, PA -- June 5, 1998 -- The United States Food and Drug Administration has approved Astra Merck Inc.’s Atacand(R) (candesartan cilexetil) for once-daily treatment of hypertension.

Atacand belongs to a group of antihypertensive medications called angiotensin II receptor blockers (ARB) which represent the first new class of antihypertensive agents in the U.S. in more than a decade.

In clinical trials involving more than 7000 hypertensive patients, Atacand has been shown to reduce blood pressure in a consistent and dose-dependent manner over a 24-hour period. In clinical trials, treatment with Atacand has been well tolerated with an adverse event rate similar to placebo.

Adverse experiences that occurred in at least one percent of patients treated with Atacand and at a higher incidence versus placebo included back pain, dizziness, upper respiratory tract infection, pharyngitis and rhinitis. Atacand should not be used in women who are pregnant or by people who are allergic to any component of the medication.

Atacand has been available in a number of European countries since 1997 and is also being studied to explore its use in other cardiovascular disorders.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities